Smokers with squamous cell carcinoma of the head and neck (SCCHN) have a particularly poor prognosis when compared with human papillomavirus-positive SCCHN. Here, we present case reports of two smokers with SCCHN treated with cetuximab-based therapy, highlighting the potential benefit of cetuximab before definitive chemoradiotherapy in patients with poor performance status as well as cetuximab rechallenge after progression. We conclude that cetuximab demonstrated notable effectiveness in two patients at high risk for poor prognosis, yielding a durable response in one and retaining activity on rechallenge in the other.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677711 | PMC |
| http://dx.doi.org/10.1159/000441019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis.
J Gastrointest Cancer
December 2024
Medical Oncology Department, BC Cancer Agency, University of British Columbia, Vancouver, Canada.
Background: Metastatic colorectal cancer (mCRC) remains a significant clinical challenge. While anti-EGFR inhibitors have improved survival rates, their long-term efficacy is limited by disease progression, which is often associated with the development of acquired resistance mutations. However, some patients may regain sensitivity to anti-EGFR agents after alternative therapies, suggesting a potential benefit for rechallenge strategies.
View Article and Find Full Text PDFEfficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
J Gastrointest Cancer
October 2024
Ophir Loyola Hospital, 66063-240, Belém, PA, Brazil.
Article Synopsis
- * This study conducted a systematic review of 14 studies involving 520 patients to evaluate the safety and efficacy of re-administering anti-EGFR treatments (like cetuximab and panitumumab) to those who previously progressed after treatment.
- * Results indicated a low objective response rate (17.70%) and a moderate disease control rate (61.72%), with notable differences in effectiveness between the types of anti-EGFR therapy used, highlighting the complexities of managing metastatic CRC
Successful cetuximab rechallenge in metastatic colorectal cancer: A case report.
World J Clin Oncol
September 2024
Department of Medical Oncology, Centro Hospitalar Gaia/Espinho, Vila Nova de Gaia 4434-502, Portugal.
Article Synopsis
- Treatment for metastatic colorectal cancer (mCRC) is evolving, focusing on tumor biology and gene analysis, with cetuximab rechallenge showing promise for RAS wild-type (RAS-wt) patients.
- A case study presented a RAS-wt patient who initially treated with FOLFIRI and cetuximab had multiple successful responses and surgeries, extending his progression-free survival (PFS) to significant durations.
- The patient experienced a marked improvement after the cetuximab rechallenge, confirming the potential effectiveness of this strategy in later mCRC treatment, leading to an overall survival exceeding 5 years.
Cholangiocarcinoma, sequential chemotherapy, and prognostic tests.
Front Oncol
June 2024
Department of Oncology, MZB Foundation for Cancer Research, New York, NY, United States.
Introduction: Routine blood tests are prognostic tests for patients with cholangiocarcinoma. New drug regimens may produce a median overall survival of 2 years or more.
Methods: This single practice, IRB-approved, phase II trial examines prognostic tests, Kaplan-Meier survival, and univariate Cox regression analyses.
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial.
Clin Drug Investig
July 2024
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Background: CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic colorectal cancer (mCRC).
Objective: We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM).
Patients And Methods: Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!